Hasil Pencarian - John V. Heymach, MD

  • Menampilkan 1 - 7 hasil dari 7
Perbaiki Hasil
  1. 1
    Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib

    Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib oleh Nishan Tchekmedyian, MD, Bill Paxton, MD, PhD, Francois Lebel, MD, Lena Keossayan, BA, John V. Heymach, MD, PhD

    Diterbitkan 2020-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy

    Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy oleh Apar Pataer, MD, PhD, Annikka Weissferdt, MD, Arlene M. Correa, PhD, Ara A. Vaporciyan, MD, Boris Sepesi, MD, John V. Heymach, MD, Sabina Berezowska, MD, Tina Cascone, MD, Stephen G. Swisher, MD

    Diterbitkan 2022-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations

    Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations oleh Whitney E. Lewis, PharmD, Lingzhi Hong, MD, PhD, Frank E. Mott, MD, George Simon, MD, Carol C. Wu, MD, Waree Rinsurongkawong, MS, MS, PhD, J. Jack Lee, MS, PhD, Vincent K. Lam, MD, John V. Heymach, MD, PhD, Jianjun Zhang, MD, PhD, Xiuning Le, MD, PhD

    Diterbitkan 2021-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade–Resistant Advanced NSCLC

    Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade–Resistant Adv... oleh Marcelo V. Negrao, MD, Vassiliki A. Papadimitrakopoulou, MD, Andrew C. Price, MD, PhD, Alda L. Tam, MD, MBA, Muhammad Furqan, MD, Sandeep T. Laroia, MD, Erminia Massarelli, MS, MD, PhD, Jose Pacheco, MD, John V. Heymach, MD, PhD, Anne S. Tsao, MD, Gary V. Walker, MD, Lalit Vora, MD, David Mauro, MD, PhD, Heather Kelley, MA, James E. Wooldridge, MD, Arthur M. Krieg, MD, Jiaxin Niu, MD

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC

    Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC oleh Kaiwen Wang, PharmD, Robyn Du, BS, Sinchita Roy-Chowdhuri, MD, Ziping T. Li, MD, Lingzhi Hong, MD, Natalie Vokes, MD, Yasir Y. Elamin, MD, Celyne Bueno Hume, MD, Ferdinandos Skoulidis, MD, PhD, Carl M. Gay, MD, PhD, George Blumenschein, MD, Frank V. Fossella, MD, Anne Tsao, MD, Jianjun Zhang, MD, PhD, Niki Karachaliou, MD, Aurora O’Brate, PhD, Claudia-Nanette Gann, MD, Jeff Lewis, MS, Waree Rinsurongkawong, PhD, J. Jack Lee, PhD, MS, DDS, Don Lynn Gibbons, MD, PhD, Ara A. Vaporciyan, MD, John V. Heymach, MD, PhD, Mehmet Altan, MD, Xiuning Le, MD, PhD

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%–89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab

    Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%–89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With Fi... oleh Biagio Ricciuti, MD, PhD, Arielle Elkrief, MD, Jessica Lin, MD, Jianjun Zhang, MD, Joao V. Alessi, MD, Giuseppe Lamberti, MD, PhD, Malini Gandhi, MD, Alessandro Di Federico, MD, Federica Pecci, MD, Xinan Wang, PhD, Maisam Makarem, MD, PhD, Cassio Murilo Hidalgo Filho, MD, Teresa Gorria, MD, Arushi Saini, BS, Cindy Pabon, MD, James Lindsay, PhD, Kathleen L. Pfaff, PhD, Emma L. Welsh, BS, Mizuki Nishino, MD, Lynette M. Sholl, MD, Scott Rodig, MD, Saadettin Kilickap, MD, Petra Rietschel, MD, Debra AG. McIntyre, PhD, Jean-Francois Pouliot, MD, Mehmet Altan, MD, Justin F. Gainor, MD, John V. Heymach, MD, Adam J. Schoenfeld, MD, Mark M. Awad, MD, PhD

    Diterbitkan 2024-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets

    Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets oleh Bingnan Zhang, MD, MBA, Whitney Lewis, PharmD, C. Allison Stewart, PhD, Benjamin B. Morris, PhD, Luisa M. Solis, MD, Alejandra Serrano, MD, Yuanxin Xi, PhD, Qi Wang, PhD, Elyse R. Lopez, MD, Kyle Concannon, MD, Simon Heeke, PhD, Ximing Tang, MD, PhD, Gabriela Raso, MD, Robert J. Cardnell, PhD, Natalie Vokes, MD, George Blumenschein, MD, Yasir Elamin, MD, Frank Fosella, MD, Anne Tsao, MD, Ferdinandos Skoulidis, MD, PhD, Celyne Bueno Hume, MD, Koji Sasak, MD, PhD, Jeff Lewis, BS, Waree Rinsurongkawong, PhD, Vadeerat Rinsurongkawong, PhD, Jack Lee, PhD, Hai Tran, PhD, Jianjun Zhang, MD, PhD, Don Gibbons, MD, PhD, Ara Vaporciyan, MD, Jing Wang, PhD, Keunchil Park, MD, PhD, John V. Heymach, MD, PhD, Lauren A. Byers, MD, Carl M. Gay, MD, PhD, Xiuning Le, MD, PhD

    Diterbitkan 2024-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: